Loading stock data…
ASTELLAS PHARMA (4503.T)
TSE¥2,171+26.00 (+1.21%)
Market ClosedLast close Jun 29
Astellas Pharma Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Astellas Pharma Inc. in the Healthcare sector is trading at ¥2,171 with a market capitalization of $3.8T. Wall Street consensus targets ¥2,385 (13 analysts), implying a +9.8% move over the next 12 months. The stock is currently 20% below its 52-week high of ¥2,717, remaining 3.6% above its 200-day moving average. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +9.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (JPY) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | ¥1.30T↓ | ¥1.52T↓ | ¥1.60T↓ | ¥1.91T |
| Gross Profit | ¥1.04T↓ | ¥1.23T↓ | ¥1.31T↓ | ¥1.56T |
| Operating Income | ¥130.96B↓ | ¥131.56B↑ | ¥18.95B↓ | ¥40.25B |
| Net Income | ¥124.09B↑ | ¥98.71B↑ | ¥17.05B↓ | ¥50.75B |
Peer Comparison
JNJUNHPFE
Fundamentals
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥3.77T
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
12.99
Beta
Defensive asset. Lower volatility than the S&P 500.
0.07
Div Yield
Strong income play. Yield provides a meaningful total return floor.
374.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.44%
Volume
Today's trading volume
10.72M
Recent News
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230 million to a gene editing startup and Merck KGaA struck a “build-to-buy” deal.
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State S
Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
Astellas Pharma (TSE:4503) Stock Valuation After KRAS Trial Progress And AI Overhaul
Internal overhaul and KRAS trial move Astellas into investor focus Astellas Pharma (TSE:4503) has drawn fresh attention after internalizing its clinical operations, adopting AI tools in drug development, and advancing its KRAS-targeting therapy setidegrasib into a phase 3 pancreatic cancer trial. See our latest analysis for Astellas Pharma. The stock’s recent 30 day share price return is down 10% and the 90 day share price return is down 9%, while the 1 year total shareholder return of 60%...